TY  - JOUR
AU  - Aranda, Enrique
AU  - Vieitez, Jose Maria
AU  - Gomez-España, Auxiliadora
AU  - Gil Calle, Silvia
AU  - Salud-Salvia, Antonieta
AU  - Graña, Begoña
AU  - Garcia-Alfonso, Pilar
AU  - Rivera, Fernando
AU  - Quintero-Aldana, Guillermo Alfonso
AU  - Reina-Zoilo, Juan Jose
AU  - Gonzalez-Flores, Encarnacion
AU  - Salgado Fernandez, Mercedes
AU  - Guillen-Ponce, Carmen
AU  - Garcia-Carbonero, Rocio
AU  - Safont, Maria Jose
AU  - La Casta Munoa, Adelaida
AU  - Garcia-Paredes, Beatriz
AU  - Lopez Lopez, Rafael
AU  - Sastre, Javier
AU  - Diaz-Rubio, Eduardo
PY  - 2020
DO  - 10.1136/esmoopen-2020-000944
UR  - http://hdl.handle.net/10668/16545
T2  - ESMO open
AB  - 5-Fluorouracil/leucovorin, oxaliplatin, irinotecan (FOLFOXIRI) plus bevacizumab is more effective than doublets plus bevacizumab as first-line therapy for metastatic colorectal cancer, but is not widely used because of concerns about toxicity and lack...
LA  - en
PB  - Elsevier BV
KW  - FOLFOX
KW  - FOLFOXIRI
KW  - bevacizumab
KW  - circulating tumor cells
KW  - colorectal cancer
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Bevacizumab
KW  - Camptothecin
KW  - Colorectal Neoplasms
KW  - Fluorouracil
KW  - Humans
KW  - Leucovorin
KW  - Neoplastic Cells, Circulating
KW  - Organoplatinum Compounds
TI  - FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial.
TY  - research article
VL  - 5
ER  -